Advertisement

Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps

  • Silvia Di GiacomoEmail author
  • Oscar Briz
  • Maria J. Monte
  • Laura Sanchez-Vicente
  • Lorena Abete
  • Elisa Lozano
  • Gabriela Mazzanti
  • Antonella Di Sotto
  • Jose J. G. MarinEmail author
Molecular Toxicology
  • 112 Downloads

Abstract

Several ATP-binding cassette (ABC) proteins reduce intracellular concentrations of antitumor drugs and hence weaken the response of cancer cells to chemotherapy. Accordingly, the inhibition of these export pumps constitutes a promising strategy to chemosensitize highly chemoresistant tumors, such as hepatocellular carcinoma (HCC). Here, we have investigated the ability of β-caryophyllene oxide (CRYO), a naturally occurring sesquiterpene component of many essential oils, to inhibit, at non-toxic doses, ABC pumps and improve the response of HCC cells to sorafenib. First, we have obtained a clonal subline (Alexander/R) derived from human hepatoma cells with enhanced multidrug resistance (MDR) associated to up-regulation (mRNA and protein) of MRP1 and MRP2. Analysis of fluorescent substrates export (flow cytometry) revealed that CRYO did not affect the efflux of fluorescein (MRP3, MRP4 and MRP5) but inhibited that of rhodamine 123 (MDR1) and calcein (MRP1 and MRP2). This ability was higher for CRYO than for other sesquiterpenes assayed. CRYO also inhibited sorafenib efflux, increased its intracellular accumulation (HPLC–MS/MS) and enhanced its cytotoxic response (MTT). For comparison, the effect of known ABC pumps inhibitors was also determined. They induced strong (diclofenac on MRPs), modest (verapamil on MDR1) or null (fumitremorgin C on BCRP) effect on sorafenib efflux and cytotoxicity. In the mouse xenograft model, the response to sorafenib treatment of subcutaneous tumors generated by mouse hepatoma Hepa 1–6/R cells, with marked MDR phenotype, was significantly enhanced by CRYO co-administration. In conclusion, at non-toxic dose, CRYO is able to chemosensitizating liver cancer cells to sorafenib by favoring its intracellular accumulation.

Keywords

Chemotherapy Liver cancer Multidrug resistance Sesquiterpenes Tyrosine kinase inhibitor 

Notes

Acknowledgements

This study was supported by the CIBERehd (EHD15PI05/2016) and Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain (PI16/00598, co-funded by European Regional Development Fund/European Social Fund, “Investing in your future”); Spanish Ministry of Economy, Industry and Competitiveness (SAF2016-75197-R); Junta de Castilla y Leon (SA063P17); Fundación Mutua Madrileña, Spain (Call 2015); Fundación Samuel Solórzano Barruso, Spain (FS/7-2016, FS/8-2017 and FS/13-2017); AECC Scientific Foundation (2017/2020), Spain. S. Di Giacomo and A. Di Sotto were supported by the “Enrico and Enrica Sovena” Foundation (Italy); S. Di Giacomo was also financed by the Italian Society of Pharmacology (SIF).

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

Supplementary material

204_2019_2395_MOESM1_ESM.docx (555 kb)
Supplementary material 1 (DOCX 555 KB)

References

  1. Ambroz M, Bousova I, Skarka A et al (2015) The influence of sesquiterpenes from Myrica rubra on the antiproliferative and pro-oxidative effects of doxorubicin and its accumulation in cancer cells. Molecules 20(8):15343–15358.  https://doi.org/10.3390/molecules200815343 CrossRefGoogle Scholar
  2. Briz O, Serrano MA, Macias RI, Marin JJ (2000) Overcoming cisplatin resistance in vitro by a free and liposome-encapsulated bile acid derivative: BAMET-R2. Int J Cancer 88(2):287–292CrossRefGoogle Scholar
  3. Briz O, Macias RI, Vallejo M, Silva A, Serrano MA, Marin JJ (2003) Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors. Mol Pharmacol 63(3):742–750CrossRefGoogle Scholar
  4. Brozik A, Hegedus C, Erdei Z et al (2011) Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol 7(5):623–642.  https://doi.org/10.1517/17425255.2011.562892 CrossRefGoogle Scholar
  5. Chen J, Jin R, Zhao J et al (2015) Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett 367(1):1–11.  https://doi.org/10.1016/j.canlet.2015.06.019 CrossRefGoogle Scholar
  6. Chen W, Xiao W, Zhang K et al (2016) Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: preliminary clinical evidence. Sci Rep 6:22976.  https://doi.org/10.1038/srep22976 CrossRefGoogle Scholar
  7. Choi CH (2005) ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 5:30.  https://doi.org/10.1186/1475-2867-5-30 CrossRefGoogle Scholar
  8. de Oliveira CC, de Oliveira CV, Grigoletto J et al (2016) Anticonvulsant activity of beta-caryophyllene against pentylenetetrazol-induced seizures. Epilepsy Behav 56:26–31.  https://doi.org/10.1016/j.yebeh.2015.12.040 CrossRefGoogle Scholar
  9. de Souza GA, da Silva NC, de Souza J et al (2017) In vitro and in vivo antimalarial potential of oleoresin obtained from Copaifera reticulata Ducke (Fabaceae) in the Brazilian Amazon rainforest. Phytomedicine 24:111–118.  https://doi.org/10.1016/j.phymed.2016.11.021 CrossRefGoogle Scholar
  10. Di Sotto A, Maffei F, Hrelia P, Castelli F, Sarpietro MG, Mazzanti G (2013) Genotoxicity assessment of beta-caryophyllene oxide. Regul Toxicol Pharmacol 66(3):264–268.  https://doi.org/10.1016/j.yrtph.2013.04.006 CrossRefGoogle Scholar
  11. Di Giacomo S, Mazzanti G, Di Sotto A (2016) Mutagenicity of cigarette butt waste in the bacterial reverse mutation assay: the protective effects of beta-caryophyllene and beta-caryophyllene oxide. Environ Toxicol 31(11):1319–1328.  https://doi.org/10.1002/tox.22136 CrossRefGoogle Scholar
  12. Di Giacomo S, Di Sotto A, Mazzanti G, Wink M (2017) Chemosensitizing properties of beta-caryophyllene and beta-caryophyllene oxide in combination with doxorubicin in human cancer cells. Anticancer Res 37(3):1191–1196.  https://doi.org/10.21873/anticanres.11433 CrossRefGoogle Scholar
  13. Di Giacomo S, Abete L, Cocchiola R, Mazzanti G, Eufemi M, Di Sotto A (2018) Caryophyllane sesquiterpenes inhibit DNA-damage by tobacco smoke in bacterial and mammalian cells. Food Chem Toxicol 111:393–404.  https://doi.org/10.1016/j.fct.2017.11.018 CrossRefGoogle Scholar
  14. Gillet JP, Gottesman MM (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596:47–76.  https://doi.org/10.1007/978-1-60761-416-6_4 CrossRefGoogle Scholar
  15. Hanusova V, Caltova K, Svobodova H et al (2017) The effects of beta-caryophyllene oxide and trans-nerolidol on the efficacy of doxorubicin in breast cancer cells and breast tumor-bearing mice. Biomed Pharmacother 95:828–836.  https://doi.org/10.1016/j.biopha.2017.09.008 CrossRefGoogle Scholar
  16. Herraez E, Gonzalez-Sanchez E, Vaquero J et al (2012) Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Mol Pharm 9(9):2565–2576.  https://doi.org/10.1021/mp300178a CrossRefGoogle Scholar
  17. Herraez E, Lozano E, Macias RI et al (2013) Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology 58(3):1065–1073.  https://doi.org/10.1002/hep.26425 CrossRefGoogle Scholar
  18. Ishida T (2005) Biotransformation of terpenoids by mammals, microorganisms, and plant-cultured cells. Chem Biodivers 2(5):569–590.  https://doi.org/10.1002/cbdv.200590038 CrossRefGoogle Scholar
  19. Kaneda N, Pezzuto JM, Kinghorn AD et al (1992) Plant anticancer agents, L. cytotoxic triterpenes from Sandoricum koetjape stems. J Nat Prod 55(5):654–659CrossRefGoogle Scholar
  20. Kato A, Miyazaki M, Ambiru S et al (2001) Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 78(2):110–115CrossRefGoogle Scholar
  21. Kim C, Cho SK, Kim KD et al (2014) Beta-caryophyllene oxide potentiates TNFalpha-induced apoptosis and inhibits invasion through down-modulation of NF-kappaB-regulated gene products. Apoptosis 19(4):708–718.  https://doi.org/10.1007/s10495-013-0957-9 CrossRefGoogle Scholar
  22. Korita PV, Wakai T, Shirai Y et al (2010) Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep 23(4):965–972Google Scholar
  23. Kubo I, Chaudhuri SK, Kubo Y et al (1996) Cytotoxic and antioxidative sesquiterpenoids from Heterotheca inuloides. Planta Med 62(5):427–430.  https://doi.org/10.1055/s-2006-957932 CrossRefGoogle Scholar
  24. Lee JS, Chu IS, Heo J et al (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40(3):667–676.  https://doi.org/10.1002/hep.20375 CrossRefGoogle Scholar
  25. Legault J, Dahl W, Debiton E, Pichette A, Madelmont JC (2003) Antitumor activity of balsam fir oil: production of reactive oxygen species induced by alpha-humulene as possible mechanism of action. Planta Med 69(5):402–407.  https://doi.org/10.1055/s-2003-39695 CrossRefGoogle Scholar
  26. Li J, Kumar P, Anreddy N et al (2017) Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: in vitro and in vivo studies. Oncotarget 8(55):93785–93799.  https://doi.org/10.18632/oncotarget.21078 Google Scholar
  27. Llovet JM, Hernandez-Gea V (2014) Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 20(8):2072–2079.  https://doi.org/10.1158/1078-0432.CCR-13-0547 CrossRefGoogle Scholar
  28. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390.  https://doi.org/10.1056/NEJMoa0708857 CrossRefGoogle Scholar
  29. Lozano E, Monte MJ, Briz O et al (2015) Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). J Control Release 216:93–102.  https://doi.org/10.1016/j.jconrel.2015.08.022 CrossRefGoogle Scholar
  30. Marin JJG, Briz O, Herraez E et al (2018a) Molecular bases of the poor response of liver cancer to chemotherapy. Clin Res Hepatol Gastroenterol 42(3):182–192.  https://doi.org/10.1016/j.clinre.2017.12.006 CrossRefGoogle Scholar
  31. Marin JJG, Lozano E, Herraez E et al (2018b) Chemoresistance and chemosensitization in cholangiocarcinoma. Biochim Biophys Acta 1864(4 Pt B):1444–1453  https://doi.org/10.1016/j.bbadis.2017.06.005 CrossRefGoogle Scholar
  32. Markwell MA, Haas SM, Bieber LL, Tolbert NE (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87(1):206–210CrossRefGoogle Scholar
  33. Munoz-Martinez F, Lu P, Cortes-Selva F et al (2004) Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance. Cancer Res 64(19):7130–7138.  https://doi.org/10.1158/0008-5472.CAN-04-1005 CrossRefGoogle Scholar
  34. Oliveira-Tintino CDM, Pessoa RT, Fernandes MNM et al (2018) Anti-inflammatory and anti-edematogenic action of the Croton campestris A. St.-Hil (Euphorbiaceae) essential oil and the compound beta-caryophyllene in in vivo models. Phytomedicine 41:82–95.  https://doi.org/10.1016/j.phymed.2018.02.004 CrossRefGoogle Scholar
  35. Park KR, Nam D, Yun HM et al (2011) Beta-caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation. Cancer Lett 312(2):178–188.  https://doi.org/10.1016/j.canlet.2011.08.001 CrossRefGoogle Scholar
  36. Rinninella E, Cerrito L, Spinelli I et al (2017) Chemotherapy for hepatocellular carcinoma: current evidence and future perspectives. J Clin Transl Hepatol 5(3):235–248.  https://doi.org/10.14218/JCTH.2017.00002 Google Scholar
  37. Sibanda S, Chigwada G, Poole M et al (2004) Composition and bioactivity of the leaf essential oil of Heteropyxis dehniae from Zimbabwe. J Ethnopharmacol 92(1):107–111.  https://doi.org/10.1016/j.jep.2004.02.010 CrossRefGoogle Scholar
  38. Sikkema J, de Bont JA, Poolman B (1994) Interactions of cyclic hydrocarbons with biological membranes. J Biol Chem 269(11):8022–8028Google Scholar
  39. Sun Z, Zhao Z, Li G et al (2010) Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori 96(1):90–96CrossRefGoogle Scholar
  40. Tomonari T, Takeishi S, Taniguchi T et al (2016) MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Oncotarget 7(6):7207–7215.  https://doi.org/10.18632/oncotarget.6889 CrossRefGoogle Scholar
  41. Vander Borght S, Komuta M, Libbrecht L et al (2008) Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 28(10):1370–1380.  https://doi.org/10.1111/j.1478-3231.2008.01889.x CrossRefGoogle Scholar
  42. Velaei K, Samadi N, Soltani S, Barazvan B, Soleimani Rad J (2017) NFkappaBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer. Breast Cancer 24(4):552–561.  https://doi.org/10.1007/s12282-016-0738-8 CrossRefGoogle Scholar
  43. Wagner H (2011) Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia 82(1):34–37.  https://doi.org/10.1016/j.fitote.2010.11.016 CrossRefGoogle Scholar
  44. Wakamatsu T, Nakahashi Y, Hachimine D, Seki T, Okazaki K (2007) The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol 31(6):1465–1472Google Scholar
  45. Wang Q, Zhong YJ, Yuan JP et al (2013) Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study. J Transl Med 11:192.  https://doi.org/10.1186/1479-5876-11-192 CrossRefGoogle Scholar
  46. Wang H, Qian Z, Zhao H et al (2015) CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells. Mol Med Rep 12(3):3902–3908.  https://doi.org/10.3892/mmr.2015.3871 CrossRefGoogle Scholar
  47. Wang H, Jia XH, Chen JR et al (2016) HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway. Int J Oncol 49(6):2529–2537.  https://doi.org/10.3892/ijo.2016.3738 CrossRefGoogle Scholar
  48. Wink M (2008) Evolutionary advantage and molecular modes of action of multi-component mixtures used in phytomedicine. Curr Drug Metab 9(10):996–1009CrossRefGoogle Scholar
  49. Wink M, Ashour ML, El-Readi MZ (2012) Secondary metabolites from plants inhibiting ABC transporters and reversing resistance of cancer cells and microbes to cytotoxic and antimicrobial agents. Front Microbiol 3:130.  https://doi.org/10.3389/fmicb.2012.00130 CrossRefGoogle Scholar
  50. Zhu M, Li W, Lu Y et al (2016) Alpha fetoprotein antagonizes apoptosis induced by paclitaxel in hepatoma cells in vitro. Sci Rep 6:26472.  https://doi.org/10.1038/srep26472 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Physiology and Pharmacology “V. Erspamer”Sapienza University of RomeRomeItaly
  2. 2.Laboratory of Experimental Hepatology and Drug Targeting (HEVEFARM), IBSALUniversity of SalamancaSalamancaSpain
  3. 3.Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd)Carlos III National Institute of HealthMadridSpain
  4. 4.Department of Physiology and PharmacologyUniversity of SalamancaSalamancaSpain

Personalised recommendations